Plunkett Research Online: InNexus Biotechnology Inc.

INNEXUS BIOTECHNOLOGY INC. (IXS:TSX) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

InNexus Biotechnology Inc is engaged in commercializing the next generation of monoclonal antibodies based on its DXL™ technology, which improves the potency of existing antibody products while opening new markets and disease applications......



InNexus Biotechnology Inc.
Ticker: IXS
Exchange: TSX
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 480 862-7500
Fax: 1 604 687-0043
Address: 1500 Royal Centre
1055 West Georgia Street
Vancouver, BC V6E 4N7 Canada

Types Of Business
Industry Ranks

Industry NAICS code:

Pharmaceuticals, Biopharmaceuticals, Generics and Drug Manufacturing
ContactsDescription
Jeff MorhetCEO/Chairman of the Board/Director/President
David PetullaCFO/Vice President
See More
InNexus Biotechnology Inc is engaged in commercializing the next generation of monoclonal antibodies based on its DXL™ technology, which improves the potency of existing antibody products while opening new markets and disease applications......See More See More

Auditor: KPMG LLP
Legal Advisor:
$USD, In whole numbers,
except marked * or %
2010
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and AffiliatesTop Salaries
NameTitleSalary (CAD)Bonus (CAD)
Other ThoughtsCorporate Culture

Apparent Female Officers or Directors: